For those who are excited about these sales by Dr. V keep in mind that through the 2012 awards he has options for 850,000 shares at exercise prices from eighty cents to six dollars and change which are exercisable at various times over the next ten years . Dr Link has + one million two hundred thousand.
Both have major articles on Immunotherapy as the next big think in cancer treatments today . "Bristol-Myers, Merck and Roche Develop Drugs to Zap Tumors Via Immune System " WSJ , and "Breaking Through Cancer's Sheild" NYT
Quick look the good / seasoned management / board / corporate partnership / . The not as good / most advanced is Phase 1b product licensed to GSK / unproven platform / bio IPO valuation in hot bio market. Could be great but to soon for me with out more development .
I 'm not sure of the # probably several dozen. Currently I own for me relatively large similarly sized positions in NLNK ,SGEN , SRPT ,ACAD , and PCYC . I also own BMY and AMGN which I bought after they acquired MEDX and MITI which I had large positions in prior to the takeouts. As you can see I'm diversified regarding NLNK I love the concept of using ones own immune system as a treatment for cancer both MEDX and MITI fit into the same category. I'm impressed by their results and think both of their platforms are unique approaches with very large and exciting potential !
I understand your logic , but for me it's like saying your a little bit pregnant , for me one is likely either to make 14 or lose 30+ and that's not a bet that would appeal to me.
Risk reward for the shorts in my opinion. If Hyper Acute fails stock declines 70% cover at $4 make $14. If HP succeeds stock opens up $32 at $50. So if your short you can lose $32 or make $14 if your right! Seems like a lousy bet to me!
Regarding the short interest . I've been investing in r&d biotech since the 1980's and big short interest is more the norm than the exception. One example I have owned SGEN for five years bought below $10 and for a couple of those years while the stock price went from $10 to $30 the short interest exceeded 30%. Now + $40 so big short interest in of itself can provide buyers and fuel on the upside if the news in the clinic is positive.
Sage you may not believe it but Doctors are allowed to invest in biotech and often do and they can and do often make comments on stock MB's . Is that the way you try to argue your point of view by calling someone a liar then you can ignore their argument ? Your comment was uncalled for and seemed stupid to me!
1, Final overall survival results 4yr 5yr from Phase II . 2, begin additional trials IDO melanoma, new IDO formulation , & HyperAcute renal. 3, Major non Us partnership HyperP.